Hi-Impacts

Company Overview

Snapshot

Founded in June 2012 by Eddy Papriov and Itzhak Fridman, Hi-Impacts operates with 1–10 employees. The company focuses on developing novel medical therapies using its proprietary acoustic pulse technology.

Business overview

Hi-Impacts is a medical device company specializing in noninvasive, non-drug therapies for various diseases. The company's core technology is a proprietary acoustic pulse technology (APT) device, also known as shock wave therapy, specifically designed for medical applications. This technology is utilized to treat inflammatory, ischemic diseases, and to facilitate fracture fusion. Hi-Impacts' patented APT device is compact and cost-effective, designed for treatments over large areas, enabling broad application across the body in a short timeframe. The company operates within the Health Tech & Life Sciences sector, with a focus on Medical Devices and Medical Treatment & Therapeutics, serving the healthcare industry globally.

Company Intelligence Q&A

What is Hi-Impacts' primary focus?

Hi-Impacts is a medical device company dedicated to developing novel, noninvasive, non-drug therapies for orthopedic, vascular, urologic, and other diseases.

What technology does Hi-Impacts utilize?

Hi-Impacts has developed a proprietary Acoustic Pulse Technology (APT) device, also referred to as shock wave technology, specifically engineered for medical applications.

Who are the founders of Hi-Impacts?

Hi-Impacts was founded by Eddy Papriov, who also serves as CEO, and Itzhak Fridman, the CSO.

What types of conditions does Hi-Impacts' technology address?

The company's patented APT interventions are designed to treat inflammatory and ischemic diseases, as well as to aid in fracture fusion.

What are the key features of Hi-Impacts' APT device?

Hi-Impacts' patented APT device is characterized by its compact size, cost-effectiveness, and its ability to treat large areas (50x350 mm) of the body efficiently.